Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives $10.53 Consensus Target Price from Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have been assigned a consensus rating of “Hold” from the twenty analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $10.53.

A number of analysts have commented on the stock. Raymond James reiterated a “market perform” rating on shares of Sage Therapeutics in a research report on Thursday, October 10th. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Scotiabank reduced their target price on Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a report on Wednesday, October 30th. Piper Sandler reduced their price objective on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Finally, Oppenheimer lowered their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday, October 30th.

Sage Therapeutics Stock Down 0.8 %

Sage Therapeutics stock opened at $7.44 on Friday. The business’s 50-day simple moving average is $5.64 and its 200 day simple moving average is $7.53. The stock has a market cap of $455.13 million, a price-to-earnings ratio of -1.33 and a beta of 0.91. Sage Therapeutics has a 12-month low of $4.62 and a 12-month high of $27.67.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The firm’s revenue for the quarter was up 337.1% compared to the same quarter last year. During the same period last year, the business posted ($2.81) EPS. As a group, sell-side analysts expect that Sage Therapeutics will post -6.53 EPS for the current year.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC grew its holdings in shares of Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock valued at $128,000 after acquiring an additional 1,486 shares in the last quarter. Headlands Technologies LLC boosted its position in Sage Therapeutics by 245.3% during the second quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,782 shares during the last quarter. Geode Capital Management LLC grew its stake in Sage Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after purchasing an additional 3,757 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Sage Therapeutics by 21.7% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 45,738 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 8,166 shares in the last quarter. 99.22% of the stock is owned by institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.